Syneron Recognizes Twenty Years of Innovation at the 2012 American Academy of Dermatology Conference
March 15 2012 - 11:30AM
Marketwired
Syneron Medical Ltd. (NASDAQ: ELOS), www.syneron.com, the global
leader in medical aesthetic products and technology, plans a
significant presence at the 2012 American Academy of Dermatology
conference to be held on March 16-20, 2012 in San Diego,
California. Syneron will recognize the twentieth anniversary of the
invention of Intense Pulse Light -- a milestone that remains a
beacon of the company's commitment to innovation and new
advancements in medical aesthetics. "Intense Pulse Light
technology, patented by our founder Shimon Eckhouse, Ph.D, launched
a new era of technological advancements that dramatically expanded
the market and served to meet the multicultural demand more safely
and effectively," said Louis P. Scafuri, Chief Executive Officer of
Syneron. "This progress led to the development of Syneron and its
principal lives on in many of our products to date."
The development of IPL in 1992 paved the road for new theories
that provided safe and predictable treatment options for patients,
regardless of skin type, including Syneron's own proprietary
technology -- electro-optical synergy or elōs®. "I've been
fortunate to be a part of the evolution of medical aesthetics
starting from the days when it was really the best kept secret in
dermatology to the worldwide phenomenon that it is today," said
Vince Afsahi, M.D. board certified Dermatologist and Assistant
Clinical Professor of Dermatology at the University of Southern
California. "Having worked with many technologies in my practice
I've always leaned towards Syneron's elōs based solutions because
it caters to a growing segment in my practice that delivers
excellent treatment options due to the high safety profile of this
technology."
Paved with innovation and built on success, Syneron presses
forward on the Road to Rejuvenation with the recent release of
eTwo™ -- a tabletop platform device that pairs Syneron's
proprietary elōs technology with the company's globally successful
Sublative™ treatment for the industry's most comprehensive solution
to facial rejuvenation. "Sublative has been my go-to application
for quite some time now -- the versatility of treatment options of
Sublative coupled with its consistent response rate on all skin
types and age groups makes it a joy to work with," said Stephen
Eubanks, M.D. board certified Dermatologist and Medical Director at
the Dermatology & Laser Center in Denver, Colorado. "The
addition of Sublime™ adds a promising new feature to the platform
that allows us to bulk heat the deep layers of the skin taking over
where Sublative leaves off."
According to Shimon Eckhouse, Ph.D, founder and Chairman of the
Board of Syneron, "The concept that drove the invention of IPL was
further improved with the development of elōs and continues on
today with products like the eTwo. We aim to offer exciting and
innovative solutions that deliver predictable and safe results to
better meet the needs and expectations of our medical aesthetic
community."
Attendees at the 2012 American Academy of Dermatology conference
can view elōs based technologies, the eTwo and the complete product
offerings by Syneron and Candela at booth #1711. This includes:
GentleMax Pro®: building upon the Gold
Standard technology of the Gentle Family™ of lasers, the new
GentleMax Pro offers more power and versatility than any other
multi-wavelength hair reduction device. GentleMax Pro features the
industry's largest spot size of 18mm coupled with tremendous
fluence options and pulse width range making it a must have device
for any thriving laser hair removal practice.
CO2RE™: the latest and best of current CO2
treatment methodologies with a revolutionary new feature known as
Fusion Fractional Mode. This option allows practitioners the
ability to treat both superficial and deep skin layers
simultaneously with precision-control over the intensity, pattern
and depth of ablation without multiple handpieces, optical spots or
multiple pass techniques.
evolastin™: the world's first energy-based
dermal remodeling procedure, powered by ePrime™. This procedure
precisely targets and delivers measured radio frequency (RF) energy
directly into the deep dermis to achieve results unlike any other
energy-based procedure on the market. With a clinically validated
100% patient response rate*, evolastin is fast becoming recognized
as a major step forward in facial aesthetics.
elure Advanced Skin Lightening™ System:
winner of allure Magazine's 'Best of Beauty' award in the "Big
Breakthroughs" category in 2011. The first and only skin lightening
topical that employs Melanozyme™, the novel natural enzyme found
only in elure to improve appearance by temporarily reducing
melanin.
To learn more about Syneron's Road to Rejuvenation visit
www.roadtorejuvenation.com. For more information about Syneron and
Candela's broad product offering, visit www.syneron.com.
* Alexiades-Armenakas et al Arch Dermatol April 2010
About Syneron Medical Ltd. Syneron Medical
Ltd. -- a company devoted to real technology, real science and real
results -- is the leading global aesthetic device company with a
comprehensive product portfolio and a global distribution
footprint. The Company's technology enables physicians to provide
advanced solutions for a broad range of medical-aesthetic
applications including body contouring, hair removal, wrinkle
reduction, rejuvenation of the skin's appearance through the
treatment of superficial benign vascular and pigmented lesions, and
the treatment of acne, leg veins and cellulite. The Company sells
its products under two distinct brands, Syneron and Candela. The
Company's aspiration and commitment to innovation expands Syneron's
offering beyond medical device into the largest in-demand
applications in beauty -- skin lightening. Founded in 2000, the
corporate, R&D, and manufacturing headquarters for Syneron
Medical Ltd. are located in Israel. Syneron also has R&D and
manufacturing operations in the US. The company markets and
services and supports its products in 86 countries. It has offices
in North America, France, Germany, Italy, Portugal, Spain, UK,
Australia, China, Japan, and Hong Kong and distributors worldwide.
Additional information can be found at www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Further, any statements
that are not statements of historical fact (including statements
containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including the risk that the businesses
of Syneron and Candela may not be integrated successfully; the risk
that the merger transaction with Candela may involve unexpected
costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to
realize than expected; the risk that disruptions from the merger
transaction make it more difficult to maintain relationships with
customers, employees, or suppliers; as well as the risks set forth
in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F,
and the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these
factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results,
performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. Syneron Medical Ltd. anticipates that subsequent
events and developments will cause its expectations and beliefs to
change. However, while Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential
impact of any future dispositions or strategic transactions that
may be undertaken. These forward-looking statements should not be
relied upon as representing Syneron Medical Ltd.'s views as of any
date after the date of this document.
Contacts: Syneron - Public Relations Email Contact Asaf
Alperovitz Chief Financial Officer + 972 73 244 2283 Zack Kubow The
Ruth Group 646-536-7020
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Historical Stock Chart
From Jul 2023 to Jul 2024